Research programme: antisense RNA therapeutics - Ionis Pharmaceuticals
Latest Information Update: 22 Aug 2024
At a glance
- Originator Ionis Pharmaceuticals
- Developer Ionis Pharmaceuticals; Metagenomi
- Class Antihypertensives; Antisense RNA; Cardiovascular therapies
- Mechanism of Action Angiotensinogen expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cardiovascular disorders; Resistant hypertension; Transthyretin-related hereditary amyloidosis